Why is this ASX biotech share leaping 14% today?

Human trial success is boosting this ASX biotech share today.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Vectus Biosystems share price is soaring 14% today 
  • The company is working on treatment for high blood pressure 
  • Trial results showed no adverse events in humans 

The S&P/ASX 200 Health Care Index (ASX: XHJ) is in the red today, but one ASX biotech share is beating the trend.

The Vectus Biosystems Ltd (ASX: VBS) share price is soaring 13.6%, currently trading at $1.25. In contrast, the ASX 200 Health Care Index is down 0.57% at the time of writing.

So why is this ASX biotech share having such a good day?

Human trial success

Vectus is working on treatments for fibrosis and high blood pressure to combat heart, kidney and liver diseases.

The company's lead compound is VB0004 to treat high blood pressure and hardening functional tissue.

In today's news, the company reported the results of the Single Ascending Dose Study for a human clinical trial. Five doses of VB0004 were administered with no adverse events to date. The 300mg dose significantly added to the therapeutic safety margin for VB0004.

Pharmacokinetic analysis showed the plasma half-life is 17 to 17.5 hours and maximal concentration after dosing takes place at six to eight hours. Vectus said this showed VB0004 was responsive to one dose per day.

A Multiple Ascending Dose (MAD) study involving the daily doses of 10mg for 14 days of VB004 to patients also showed no adverse events. A second group of people will now be involved in the MAD study, with three people already enrolled.

The results were reviewed by the Trial Safety Review Committee.

Vectus chair Ron Shiner said:

This is an exciting development in Vectus' journey of validating an orally-dosable anti-fibrotic, which could not just slow down disease progression, but in fact, potentially provide clinical reversal of existing damage in a truly transformational agent.

Vectus share price snapshot

Vectus shares have rocketed nearly 29% in the past 12 months, but they are down 11% year to date.

For perspective, the S&P/ASX 200 Index (ASX: XJO) has climbed 2% during the past year.

The ASX biotech share has a market capitalisation of about $45 million based on its current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »